Zimmer Biomet Holdings, Inc. (ZBH) Earnings Call Transcripts

Zimmer Biomet Holdings, Inc.'s Latest Earnings Call - Q2 FY2026

In the second quarter of 2026, Zimmer Biomet Holdings, Inc. reported net sales of $2.177 billion, exceeding expectations and reflecting a 4.8% growth year-over-year. Adjusted earnings per share (EPS) were $2.07, consistent with the prior year, while GAAP diluted EPS increased to $1.03 from $0.77. The company raised its full-year organic constant currency revenue guidance to a range of 2.25% to 3.25%, up from 1% to 3%, and adjusted EPS guidance to $8.47 to $8.59 from $8.40 to $8.55, indicating strong operational momentum and confidence in future growth.

Reported metrics

Guidance from management

The company raised its full-year organic constant currency revenue growth guidance to 2.25% to 3.25% and adjusted EPS guidance to $8.47 to $8.59, reflecting confidence in operational momentum and market conditions.

What management said

Look, I say that my guidance or guidance philosophy is going to be to say less and do more. We're going to take a measured approach, given all the variables that we continue to analyze, and that's what we're doing. We're confident on the guidance for the second half lots of puts and takes. We see certainly more upside than downside when we look at where we finished the first half, but we're going to go 1 quarter at a...

What analysts pressed on

Analysts raised concerns about the potential for increased pricing pressure, particularly in light of proposed Medicare cuts. There were questions regarding the sustainability of growth given the mixed performance in international markets and the impact of the ACA on procedures.

Main topics on the call

• Revenue Growth Acceleration — Zimmer Biomet achieved a 4.8% growth in net sales, driven by a 5.1% increase in hips and a 53% surge in technology sales. CEO Ivan Tornos noted, "We delivered almost 6% growth in Hips, 5.9%. Our technology business...gre...
• Guidance Upgrade — The company raised its full-year organic constant currency revenue guidance to 2.25% to 3.25% and adjusted EPS guidance to $8.47 to $8.59. Paul Stellato stated, "We are increasing our adjusted earnings per share expectat...
• Sales Force Transition — Management indicated that the transition to a specialized U.S. sales force is progressing better than expected, with low turnover and high engagement. Tornos mentioned, "The go-to-market changes are going better, if not ...
• International Market Dynamics — The international business grew 3.1%, with strong demand for the iodine core hip launch in Japan. Tornos highlighted, "We expect this first-to-the-world technology to be a meaningful growth driver in the second half of t...

Read the full Zimmer Biomet Holdings, Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 73 Zimmer Biomet Holdings, Inc. earnings call transcripts on record, spanning February 4, 2020 to August 5, 2026. Based on this history, Zimmer Biomet Holdings, Inc. reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ZBH

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

73

First call

February 4, 2020

Most recent

August 5, 2026

Reporting cadence

quarterly